- Patients with refractory or relapsed AML ( marrow blasts > 20% ), must have failed induction therapy or have relapsed after CR duration < 6 months following induction therapy, untreated or refractory to salvage chemotherapy. Relapsed AML patients with CR duration > 6 months or previously untreated patients refusing chemotherapy and not considered for treatments of higher priority are also eligible.